TEVA-INDOMETHACIN 50 MG — DIN 00337439
INDOMETHACIN : 50 MG · TEVA CANADA LIMITED · CAPSULE · wholesale supply in Canada
Health Canada status: MARKETED
What is TEVA-INDOMETHACIN?
TEVA-INDOMETHACIN 50 MG contains INDOMETHACIN : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 00337439, held by TEVA CANADA LIMITED, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 14-Jul-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TEVA-INDOMETHACIN used for?
Symptomatic treatment of Rheumatoid Arthritis, Ankylosing (Rheumatoid) Spondylitis, Osteoarthritis, Degenerative Joint Disease of the Hip, and Acute Gout.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Indometacin cost around the world?
Indometacin is listed on 10 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Bahrain publishes a retail (max); Czechia publishes a max producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Saudi Arabia | public | 16 | 18 | SAR███.██ |
| South Africa | single exit price | 10 | 14 | ZAR███.██ |
| Australia | ex-manufacturer | 2 | 8 | AUD███.██ |
| Romania | max producer price | 6 | 8 | RON███.██ |
| Bahrain | retail (max) | 3 | 3 | BHD███.██ |
| United Kingdom | hospital | 2 | 2 | GBP███.██ |
| Luxembourg | reimbursement | 2 | 2 | EUR███.██ |
| United Arab Emirates | public | 1 | 1 | AED███.██ |
| Czechia | max producer price (ex-factory) | 1 | 1 | CZK███.██ |
| Greece | producer price (ex-factory) | 1 | 1 | EUR███.██ |
58 pack listings across 44 brand entries and 9 price bases, refreshed 08 Sep 2026. Ranges span every Indometacin pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Indometacin in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
13 holders have a Canadian DIN containing Indometacin, across 31 DINs, of which 7 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| TEVA CANADA LIMITED | 5 | 2 | NTP-INDOMETHACIN, RATIO-INDOMETHACIN, TEVA-INDOMETHACIN | Sourceable in Canada |
| MINT PHARMACEUTICALS INC | 2 | 2 | MINT-INDOMETHACIN | Sourceable in Canada |
| ODAN LABORATORIES LTD | 2 | 2 | ODAN-INDOMETHACIN | Sourceable in Canada |
| AURO PHARMA INC | 1 | 1 | AURO-INDOMETHACIN | Sourceable in Canada |
| MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO. | 5 | 0 | INDOCID CAP 25MG, INDOCID CAP 50MG, INDOCID SR 75MG, INDOCID SUP 100MG, INDOCID SUP 50MG | No marketed DIN |
| RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED | 3 | 0 | RATIO-INDOMETHACIN | No marketed DIN |
| APOTEX INC | 2 | 0 | APO-INDOMETHACIN | No marketed DIN |
| FTP-PHARMACAL INC. | 2 | 0 | FTP-INDOMETHACIN | No marketed DIN |
| NOVOPHARM LIMITED | 2 | 0 | NOVO-METHACIN - 100MG SUP, NOVO-METHACIN - SUP 50MG | No marketed DIN |
| NU-PHARM INC | 2 | 0 | NU-INDO CAP 25MG, NU-INDO CAP 50MG | No marketed DIN |
| PRO DOC LIMITEE | 2 | 0 | PRO-INDO 25 CAP 25MG, PRO-INDO 50 CAP 50MG | No marketed DIN |
| RHODIAPHARM INC | 2 | 0 | RHODACINE - CAP 25MG, RHODACINE - CAP 50MG | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 50 MG |
|---|---|
| Dosage form | CAPSULE |
| Route | ORAL |
| Pack configuration (monograph) | Bottles of 100, 500 and 1000 capsules. |
| Storage | Not explicitly detailed in provided text (section 11 mentioned in TOC but text cuts off). Standard practice: Store at 15-30°C. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Indometacin |
|---|---|
| ATC code | M01AB01 |
| AHFS class | 28:08.04.92 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00337439 |
|---|---|
| DIN (unpadded, as printed on some documents) | 337439 |
| Brand name | TEVA-INDOMETHACIN |
| Generic / active ingredient | INDOMETHACIN : 50 MG |
| Market authorization holder | TEVA CANADA LIMITED |
| Health Canada schedule | Prescription |
| ATC code | M01AB01 |
| ATC anatomical main group | M — Musculo-skeletal system |
| ATC therapeutic subgroup | M01AB |
| Current status | MARKETED |
| Status date | 14-Jul-2015 |
| Original market date | 1980-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Initial: 25 mg 2-3 times/day. Increase by 25 mg weekly if needed to max 150-200 mg/day. Gout: 50 mg 3 times/day. Take with food or antacids. Use lowest effective dose for shortest duration.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
CABG surgery; 3rd trimester pregnancy; breastfeeding; severe heart failure; hypersensitivity to indomethacin/ASA/NSAIDs; active GI ulcer/bleeding; bleeding disorders; IBD; severe liver/renal impairment.
Warnings and precautions
Serious CV risk (MI, stroke); GI toxicity (bleeding, ulceration); CNS effects (headache, dizziness); may mask infection; risk of hypertension and fluid retention.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
7 of 31 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-INDOMETHACIN | 50 MG | CAPSULE | AURO PHARMA INC | MARKETED | 02499223 |
| MINT-INDOMETHACIN | 50 MG | CAPSULE | MINT PHARMACEUTICALS INC | MARKETED | 02461536 |
| MINT-INDOMETHACIN | 25 MG | CAPSULE | MINT PHARMACEUTICALS INC | MARKETED | 02461811 |
| ODAN-INDOMETHACIN | 50 MG | SUPPOSITORY | ODAN LABORATORIES LTD | MARKETED | 02231799 |
| ODAN-INDOMETHACIN | 100 MG | SUPPOSITORY | ODAN LABORATORIES LTD | MARKETED | 02231800 |
| TEVA-INDOMETHACIN | 25 MG | CAPSULE | TEVA CANADA LIMITED | MARKETED | 00337420 |
| APO-INDOMETHACIN | 25 MG | CAPSULE | APOTEX INC | DORMANT | 00611158 |
| APO-INDOMETHACIN | 50 MG | CAPSULE | APOTEX INC | DORMANT | 00611166 |
| FTP-INDOMETHACIN | 25 MG | CAPSULE | FTP-PHARMACAL INC. | CANCELLED POST MARKET | 02238442 |
| FTP-INDOMETHACIN | 50 MG | CAPSULE | FTP-PHARMACAL INC. | CANCELLED POST MARKET | 02238443 |
2 · Same class — other molecules in ATC M01AB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Diclofenac | APO-DICLO · APO-DICLO RAPIDE 50 MG TABLETS · APO-DICLO SR · AVA-DICLOFENAC · +44 more | 74 | 15 | Yes |
| Ketorolac | APO-KETOROLAC · APO-KETOROLAC INJECTABLE · JAMP KETOROLAC · KETOROLAC TROMETHAMINE INJECTION USP · +12 more | 25 | 8 | Yes |
| Indometacin | APO-INDOMETHACIN · AURO-INDOMETHACIN · FTP-INDOMETHACIN · INDOCID CAP 25MG · +18 more | 31 | 7 | Yes |
| Diclofenac, Combinations | ACT DICLO-MISO · ARTHROTEC 50 · ARTHROTEC 75 · DICLOFENAC MISOPROSTOL · +4 more | 12 | 6 | Yes |
| Sulindac | APO-SULIN TAB 150MG · APO-SULIN TAB 200MG · CLINORIL TAB 150MG · CLINORIL TAB 200MG · +6 more | 12 | 2 | Yes |
| Etodolac | ETODOLAC · GEN-ETODOLAC 200MG · GEN-ETODOLAC 300MG · NOVO-ETODOLAC 200 MG · +5 more | 12 | 0 | Not in Canada |
| Tolmetin | NOVO-TOLMETIN CAPSULES 400MG · TOLECTIN 200 TAB 200MG · TOLECTIN 400 CAP 400MG · TOLECTIN TAB 600MG | 4 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC M01A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| M01AE | Fenoprofen · Flurbiprofen · Ibuprofen · Ibuprofen, Combinations · Ketoprofen · +5 more | 398 | 101 |
| M01AH | Celecoxib · Rofecoxib | 72 | 30 |
| M01AC | Meloxicam · Piroxicam · Tenoxicam | 67 | 14 |
| M01AG | Mefenamic Acid | 7 | 1 |
| M01AX | Nabumetone | 12 | 1 |
| M01AA | Oxyphenbutazone · Phenylbutazone · Phenylbutazone, Combinations | 7 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is TEVA-INDOMETHACIN called?
The same molecule, Indometacin, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Indocid | Latin | Australia, Bahrain, Saudi Arabia |
| Arthrexin | Latin | Australia, South Africa |
| Betacin | Latin | South Africa |
| ELMETACIN | Latin | Bahrain |
| Elmetacin Solution | Latin | South Africa |
| Famethacin | Latin | South Africa |
| Flamecid | Latin | South Africa |
| INDOCOLLYRE | Latin | Czechia |
| INDYLON | Latin | Bahrain |
| Methocaps | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.